Bristol-Myers Squibb Company (ETR:BRM)

Germany flag Germany · Delayed Price · Currency is EUR
42.02
-0.30 (-0.70%)
Jun 6, 2025, 9:04 AM CET
9.50%
Market Cap 85.02B
Revenue (ttm) 44.07B
Net Income (ttm) 5.01B
Shares Out n/a
EPS (ttm) 2.47
PE Ratio 16.96
Forward PE 7.30
Dividend 2.26 (5.35%)
Ex-Dividend Date Apr 4, 2025
Volume 85
Average Volume 2,619
Open 42.02
Previous Close 42.31
Day's Range 42.02 - 42.02
52-Week Range 36.42 - 58.79
Beta 0.39
RSI 46.53
Earnings Date Jul 31, 2025

About ETR:BRM

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthrit... [Read more]

Sector Healthcare
Founded 1887
Employees 34,100
Stock Exchange Deutsche Börse Xetra
Ticker Symbol BRM
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

Bristol Myers' new cancer partnership is promising, but doesn't change our stance on the stock yet

Bristol Myers' is making a big move into next-generation cancer treatments. But there's still more to prove.

3 days ago - CNBC

Why BioNTech Stock Soared Today

Bristol Myers Squibb just agreed to shower BioNTech with cash.

3 days ago - The Motley Fool

Watch CNBC's full interview with Bristol Myers CEO Christopher Boerner

Christopher Boerner, Bristol Myers CEO, joins 'Squawk on the Street' to discuss the company's recent partnership with Biontech, the cost of the deal and much more.

3 days ago - CNBC

Bristol Myers CEO on Biontech deal: Next new frontier in treatment of cancer

Christopher Boerner, Bristol Myers CEO, joins 'Squawk on the Street' to discuss the company's recent partnership with Biontech, the cost of the deal and much more.

3 days ago - CNBC

BioNTech Stock Jumps on Bristol Myers Squibb Cancer Drug Collaboration

U.S.-listed shares of BioNTech jumped more than 15% Monday morning after the German vaccine maker announced a collaboration with Bristol Myers Squibb.

3 days ago - Investopedia

Bristol Myers Inks $11 Billion Licensing Pact With BioNTech For Bispecific Cancer Drug

BioNTech SE (NASDAQ: BNTX) and Bristol Myers Squibb & Co . (NYSE: BMY) entered into a co-development and co-commercialization agreement . The pact focuses on BioNTech’s investigational bispecific an...

3 days ago - Benzinga

Bristol Myers makes $11 billion deal with BioNTech to join the cancer-drug race

Bristol-Myers makes an $11 billion deal with BioNTech to join the new cancer-treatment game, nearly double the size of Pfizer’s deal announced two weeks earlier.

3 days ago - MarketWatch

Bristol Myers Squibb signs $11bn cancer drug deal with BioNTech

US-German partnership hopes BNT327 will compete with Merck’s bestseller Keytruda

3 days ago - Financial Times

Why the stock rally fizzled plus, our latest thinking on Goldman and Bristol Myers

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.

7 days ago - CNBC

Bristol Myers Squibb to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11, 2025. The company will take part...

8 days ago - Wallstreet:Online

Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo (nivolumab) Across Multiple Solid Tumor Indications

Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved a new Opdivo (nivolumab) formulation associated with a new route of administration (subcutaneous use [SC...

8 days ago - Wallstreet:Online

Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications

Opdivo is the first and only PD-1 inhibitor approved for subcutaneous (SC) use in the European Union Approval is based on results from the Phase 3 CheckMate -67T clinical trial which demonstrated noni...

8 days ago - Benzinga

Bristol Myers Squibb to Present Data at ASCO 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its oncology portfolio and pipeline at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting to be held ...

14 days ago - Wallstreet:Online

Bristol Myers Squibb to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its oncology portfolio and pipeline at the 2025 American Society of Clinical Oncology (ASCO ®) Annual Meeting to be h...

14 days ago - Benzinga

Major US stock indices close today lower as yields rise

The major US stock indices a closing lower on the day. The Dow industrial average was the worst performer with a decline of -1.91%. The top 10 decliners for the day: UnitedHealth Group (UNH): −5.78% N...

15 days ago - Forexlive